Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

  1. ANTHONY S. FAUCI, M.D.;
  2. BARTON F. HAYNES, M.D.;
  3. PAUL KATZ, M.D.; and
  4. SHELDON M. WOLFF, M.D.
  1. Bethesda, Maryland

    Abstract

    Eighty-five patients with Wegener's granulomatosis were studied for 21 years at the National Institutes of Health. Patients were treated with a protocol consisting of cyclophosphamide, 2 mg/kg body weight · d, together with prednisone, 1 mg/kg body weight · d, followed by conversion of the prednisone to an alternate-day regimen. Complete remissions were achieved in 79 of 85 patients (93%). The mean duration of remission for living patients was 48.2 (± 3.6) months. Twenty-three patients are off all therapy for a mean duration of 35.3 (± 6.3) months without therapy. This study provides a prospective experience with Wegener's granulomatosis and shows that long-term remissions can be induced and maintained in an extremely high number of patients by the combination of daily cyclophosphamide and alternate-day prednisone therapy.

    Article and Author Information

    • ▸From the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda. Maryland.

    • ▸Requests for reprints should be addressed to Anthony S. Fauci, M.D.; Building 10, Room 11B-13, National Institutes of Health; Bethesda, MD 20205.

    « Previous | Next Article »Table of Contents